A method for preparing heat shock protein peptide and its application in malignant tumors

By extracting and processing heat shock protein peptide from patient tumor tissue and using it in combination with monoclonal antibodies specifically targeting DR5, the shortcomings of heat shock protein peptide in the prior art in the treatment of malignant tumors are solved, and the tumor is significantly improved Killing and tumor suppression rates demonstrate the therapeutic prospects of the composition.

CN118767131BActive Publication Date: 2024-11-15SINO UNITED (BEIJING) BIOMEDICAL TECH CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411265927.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-11-15
Estimated Expiration
2044-09-11

AI Technical Summary

Technical Problem

The existing heat shock protein peptides have fewer applications in the treatment of malignant tumors, especially the combination of monoclonal antibody drugs is insufficient, resulting in insufficient efficacy.

Method used

Fresh tumor tissue or tumor cells of the patient are obtained by sterile acquisition, high-quality heat shock protein peptides are obtained through immunohistochemistry screening and multi-step treatment, combined with monoclonal antibodies specifically targeting DR5, and injected into the patient's subcutaneous treatment of malignant tumors. , and other chemotherapeutic drugs can be used in combination.

Benefits of technology

A strong tumor killing effect and tumor inhibition rate were achieved, showing the prospect of combined treatment of heat shock protein peptide and DR5 monoclonal antibody, and improving the therapeutic effect on malignant tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118767131B_ABST
    Figure CN118767131B_ABST
Patent Text Reader

Abstract

The present invention provides a method for preparing a heat shock protein peptide and its application in malignant tumors. More specifically, the present invention also obtains a heat shock protein 70 peptide by homogenizing and purifying tumor tissue or tumor cells, and the heat shock protein peptide is injected into the patient's lesion to achieve the purpose of treating malignant tumors. In addition, the heat shock protein 70 peptide has a strong tumor-killing effect after being used in combination with the monoclonal antibody specifically targeting DR5 prepared by the present invention, and has a good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the biological field, and specifically to a method for preparing a heat shock protein peptide and its application in malignant tumors. Background Art

[0002] Heat shock proteins (HSPs) are a family of proteins with important physiological functions that are induced in prokaryotic and eukaryotic cells under stress. Based on their relative molecular mass, HSPs are divided into six subfamilies: HSP100, HSP90, HSP70, HSP60, HSP40, and small heat shock proteins (sHSPs). This class of proteins is highly conserved both within and across species. HSPs function as molecular chaperones. Under stress, HSPs prevent protein denaturation by inhibiting the natural conformational changes that occur with stress, thereby maintaining normal cellular life and reducing cell damage and apoptosis. HSPs can enhance cellular tolerance to adverse environmental conditions such as high temperature, radiation, and drugs, helping cells survive these conditions. Furthermore, HSPs play an important role in cell cycle regulation and intracellular signal transduction. Research has shown that HSPs are closely associated with tumor development and progression, as well as the sensitivity of tumor tissue to drugs and radiation.

[0003] HSPs account for approximately 5%-10% of normal cells and mainly assist in the folding of newly formed peptide chains. When cells are exposed to external stimuli such as heat stimulation, pH changes, ultraviolet irradiation, hormone stimulation, pathogen infection, inflammation, etc., effector proteins bind to molecular chaperones and release heat shock factors (HSFs). Heat shock factors, as transcription factors, bind to heat shock elements (HSEs) to induce an increase in the concentration of HSPs in cells. A decrease in the concentration of free HSPs can activate heat shock factors, while high concentrations of HSPs can inhibit the activity of heat shock factors, thereby achieving a dual regulatory effect on HSPs. During stress responses, the original molecular chaperone function of HSPs is amplified, binding to denatured or abnormal proteins, and repairing incorrect folding or accelerating their degradation, thereby maintaining cell stability and reducing cell damage.

[0004] HSP70, a key member of the HSPs family, is widely found in prokaryotes and eukaryotes and is involved in the folding, assembly, and transport of numerous intracellular proteins. Its functions have been extensively studied in recent years. HSP70 expression levels are significantly correlated with tumorigenesis, malignancy, drug resistance, and metastasis. Zhu Lingqin et al., studying breast cancer tissue, found elevated HSP70 expression in breast cancer tissue, with significant differences compared to benign breast lesions. Furthermore, HSP70 expression in breast cancer correlated with clinical stage, lymph node metastasis, and tumor diameter, but not with age, menstrual status, or histological type. A study of 52 patients with colorectal liver metastases who underwent surgical resection of the primary lesion but not the liver metastases and were treated with the oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) chemotherapy regimen found that patients with high HSP70 expression had a significantly lower partial response rate than those with low HSP70 expression, suggesting that FOLFOX4 is more effective in patients with colorectal liver metastases who have low HSP70 expression compared to those with high HSP70 expression. Other studies have shown that the expression of HSP70 is related to the histological differences of non-small cell lung cancer, the presence of lymph node metastasis, clinical stage and the patient's smoking history, suggesting that HSP70 can be used as a prognostic indicator for non-small cell lung cancer.

[0005] Heat shock protein 70 has been shown to function as a potent "molecular chaperone" and immune adjuvant in tumor immunity. It can bind to a variety of tumor antigen peptides, participating in antigen presentation and processing. It acts as a "molecular adjuvant" for tumor antigen peptides in vivo, inducing specific active immunity. HSP70 plays a dual role in tumor immunity. First, as a "molecular chaperone," it participates in the functional metabolism of tumor cells, protecting them from harmful factors. Second, the heterogeneity in growth, metabolism, and differentiation between tumor cells and normal cells makes HSP70 a target carrier for tumor antigen peptides it binds to, playing a crucial role in immune responses against tumor antigens. Animal studies have shown that HSP70 molecules extracted from lung cancer, colon cancer, and melanoma cells, when used as tumor protein peptides, can induce a protective immune response in mice and reduce the risk of tumor formation. However, they have little immune response against other tumor cell lines, demonstrating that HSPs induce a relatively specific immune response. Studies have confirmed that the role of HSP70 in tumor immunity depends on the combined effects of immune responses, involving the synergistic effects of APCs, a / βT cells, Y / δT cells, and NK-like cells. Its tumor cell-killing effect is the result of a comprehensive effect. Currently, recombinant HSP70-antigen peptide complexes can be extracted from tumor tissues and used as vaccines to immunize the body and stimulate the body to produce anti-tumor specific CTL effects.

[0006] At present, there are not many studies on the use of heat shock protein peptides to treat cancer, especially the research on the combination of heat shock protein peptides with other drugs, such as monoclonal antibody drugs with good cancer treatment effects. Further development of more effective combinations is needed. Summary of the Invention

[0007] The present invention overcomes the defects of the prior art and provides a method for preparing a heat shock protein peptide and its application in malignant tumors.

[0008] More specifically, the present invention also provides a method for aseptically obtaining fresh tumor tissue or sterile tumor tissue or tumor cells without protein denaturation from a patient, confirming through immunohistochemical screening that the tumor tissue contains one or more heat shock protein peptides such as 60 / 70 / 96 / 110, and obtaining heat shock protein peptides (personalized tumor progenitor complexes) through homogenization, filtration, dialysis, purification, sterilization, and other treatments. The heat shock protein peptides that meet quality control requirements such as microorganisms, heat sources, protein qualitative and quantitative properties are then injected subcutaneously or intradermally into the patient to achieve the purpose of treating malignant tumors.

[0009] Specifically, the present invention also provides the use of heat shock protein peptides in the preparation of drugs for treating malignant tumors.

[0010] Furthermore, the medicine may also contain a second therapeutic agent.

[0011] Specifically, the second therapeutic agent is a monoclonal antibody that specifically targets DR5.

[0012] Specifically, the DR5 is one of the main receptors of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), and its functional monoclonal antibody has the activity of TRAIL inducing cell apoptosis, which can induce apoptosis of tumor cells without toxic side effects on normal cells.

[0013] Specifically, the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO: 1, and the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 2.

[0014] In some embodiments of the present invention, the heavy chain constant region has the following mutations based on the sequence shown:

[0015] L234A and L235A; or

[0016] L234A and G237A; or

[0017] L235A and G237A;

[0018] or

[0019] L234A, L235A, G237A;

[0020] Or one or more mutations selected from the following:

[0021] N297A, D265A, D270A, P238D, L328E, E233D, H268D, P271G, A330R, C226S, C229S, E233P, P331S, S267E, L328F, A330L, M252Y, S254T, T256E, N297Q, P238S, P238A, A327Q, A327G, P329A, K322A, T394D, G236R, G236A, L328R, A330S, P331S, H268A, E318A, and K320A.

[0022] The present invention relates to a method for preventing and / or treating tumors (especially malignant tumors), comprising administering a therapeutically effective amount of an anti-DR5 antibody to a subject, in combination with administering a heat shock protein peptide.

[0023] The present invention further provides a use of a DR5 antibody and a heat shock protein peptide in preparing a pharmaceutical composition for treating cancer.

[0024] More preferably, one or more chemotherapeutic drugs are further administered in combination (preferably the chemotherapeutic drug is a chemotherapeutic agent or a growth inhibitory agent, a targeted therapeutic agent (such as an antibody-drug conjugate, an antibody or an antigen-binding fragment thereof), T cells expressing chimeric antigen receptors, angiogenesis inhibitors, anti-tumor agents, cancer vaccines, adjuvants and combinations thereof, antimetabolites, antibiotics, botanicals and / or hormones, preferably cyclophosphamide, pemetrexed, platinum drugs such as cisplatin, carboplatin, oxaliplatin, doxorubicin, paclitaxel, vinca alkaloids, tamoxifen, megestrol acetate, goserelin, asparaginase and / or fluorouracil anti-tumor drugs).

[0025] In one or more embodiments of the invention, the chemotherapeutic agent or growth inhibitory agent is selected from an alkylating agent, an anthracycline, an antihormonal agent (e.g., an antiandrogen), an aromatase inhibitor, a protein kinase inhibitor (e.g., a tyrosine kinase inhibitor), a lipid kinase inhibitor, an antisense oligonucleotide, a ribozyme, an antimetabolite, a topoisomerase inhibitor, a cytotoxic agent or an antitumor antibiotic, a proteasome inhibitor, an antimicrotubule agent, an EGFR antagonist, a VEGF antagonist, a PD-1 antagonist, an angiopoietin 2 antagonist, a retinoid, a histone deacetylase inhibitor, and a combination thereof.

[0026] In one or more embodiments of the present invention, the tumor is selected from one or more of the following:

[0027] Cervical cancer (e.g., metastatic cervical cancer), endometrial cancer, lung cancer such as small cell lung cancer and non-small cell lung cancer (e.g., squamous non-small cell lung cancer or non-squamous non-small cell lung cancer), pharyngeal cancer, esophageal cancer, esophageal squamous cell carcinoma, thyroid cancer, mesothelioma, gastrointestinal cancer such as gastric cancer ((including microsatellite stable (MSS) and mismatch repair deficiency / microsatellite high instability (dMMR / MSI-H) types), such as advanced gastric cancer, gastric adenocarcinoma or gastroesophageal junction adenocarcinoma) and intestinal cancer (such as rectal cancer, colon cancer, colorectal cancer (including tuberculosis satellite stable (MSS) The following are the main diseases of the present invention: (1) hepatic cancer (such as hepatocellular carcinoma, hepatobiliary cancer), (2) pancreatic cancer (such as pancreatic cancer), renal cancer (such as ovarian cancer), fallopian tube cancer, anal epidermoid carcinoma, peritoneal cancer, glioma, glioma, recurrent glioma, skin cancer, melanoma, hematological malignancies (such as leukemia (such as acute myeloid leukemia), lymphoma (such as Hodgkin lymphoma, non-Hodgkin lymphoma), multiple sclerosis (such as myeloid leukemia), hepatitis B virus (such as melanoma), hepatitis B virus (such as hepatocellular carcinoma, hepatobiliary cancer), biliary tract cancer (such as bile duct cancer and gallbladder cancer), pancreatic cancer, pancreatic cancer, renal cancer, ovarian cancer (such as advanced ovarian cancer), fallopian tube cancer, anal epidermoid carcinoma, peritoneal cancer, glioma, glioma, recurrent glioma, skin cancer, melanoma, hematological malignancies (such as leukemia (such as acute myeloid leukemia), lymphoma (such as Hodgkin lymphoma, non-Hodgkin lymphoma), multiple sclerosis (such as myeloid leukemia), hepatitis B virus (such as hepatocellular carcinoma, hepatobiliary cancer), hepatitis B virus (such as hepatocellular carcinoma), hepatitis B virus (such as ... myeloma, B lymphoma (e.g., plasma cell carcinoma), bone cancer, sarcoma (e.g., leiomyosarcoma, rhabdomyosarcoma), osteosarcoma, chondrosarcoma, neuroblastoma, myeloma, (e.g., multiple myeloma) large cell neuroendocrine carcinoma, urothelial carcinoma (e.g., upper tract urothelial carcinoma or bladder cancer), prostate cancer (including metastatic castration-resistant prostate cancer (mCRPC)), testicular cancer, triple-negative breast cancer, peripheral T-cell lymphoma, nasopharyngeal carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR ) solid tumors, head and neck cancer, brain cancer (such as invasive brain cancer), squamous cell carcinoma, basal cell carcinoma, adenoma (such as breast cancer, thymic carcinoma, ileocecal adenocarcinoma, ampullary adenocarcinoma, pancreatic duct adenocarcinoma, mucinous or serous cystadenocarcinoma), choriocarcinoma, malignant hydatidiform mole, malignant Sertoli cell-Leydig cell tumor, malignant granular cell tumor, dysgerminoma, glioblastoma, fungal disease, Merkel cell carcinoma, intrahepatic bile duct carcinoma, Merkel cell carcinoma, squamous cell anorectal cancer, squamous cell carcinoma of the tongue, squamous cell carcinoma of the head and neck, and other hematological malignancies.

[0028] More specifically, the cancer is esophageal cancer.

[0029] In specific embodiments of the invention, the dosing regimen comprises, for example, administering a single pharmaceutical dosage unit according to a dosing cycle of twice a day to about every other day, or once every 3 days, 4 days, 5 days, 6 days, 10 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, or 6 weeks. Beneficial effects

[0030] The present invention provides a method for preparing a heat shock protein peptide and its application in treating malignant tumors. More specifically, the present invention also provides a heat shock protein 70 peptide obtained by homogenizing and purifying tumor tissue or cells. This heat shock protein peptide can be injected into a patient's lesion to treat malignant tumors. Furthermore, the combination of the heat shock protein 70 peptide and a monoclonal antibody specifically targeting DR5 produced by the present invention exhibits a strong tumor-killing effect and has promising application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 Western blot analysis of HSP70 peptide. Lane A shows the protein eluted with PBS, which does not contain the target protein. Lane B shows the HSP70 peptide eluted with the desorption buffer.

[0032] Figure 2 The results of each group's killing rate on cancer cells are shown in the figure.

[0033] Figure 3 Results of the effects of each group on tumor inhibition rate. DETAILED DESCRIPTION

[0034] Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously change or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to achieve and apply the technology of the present invention. The methods, equipment, and materials in the following implementation cases, if not otherwise specified, are conventional methods, equipment, and materials in the art and can be purchased from the market.

[0035] Example 1 Preparation of heat shock protein 70 peptide

[0036] After removing cryovials of TE-11 esophageal cancer cells (Cat. No. GOY-X6376, Shanghai Guyan Industrial) from -196°C liquid nitrogen, rapidly thaw the cells to 37°C to allow extracellular crystals to thaw rapidly. Adherent subculture was performed according to the culture instructions. Specifically, the supernatant was discarded and the cells were rinsed 1-2 times with calcium- and magnesium-free PBS. 2 ml of digestion buffer (0.25% Trypsin-0.53 mM EDTA) was added to the culture flask and incubated in a 37°C incubator for 1-2 minutes. KYSE-410 cell culture medium was added at a rate of 6-8 ml / flask. The suspension was gently stirred and aspirated. The suspension was centrifuged at 1000 RPM for 4 minutes. The supernatant was discarded and 1-2 ml of KYSE-410 cell culture medium was added and then vortexed to mix. The cell suspension was divided into a new dish or flask containing 8 ml of KYSE-410 cell culture medium at a ratio of 1:2 to 1:5.

[0037] The cells in logarithmic growth phase were incubated at 43℃ for 12h and then recovered at 37℃ for 2h. 5.0×10 8 For each cell, add 4 times the volume of cell lysis buffer and lyse the cells on ice. Centrifuge at 100,000 rpm for 90 min at 4°C, take the supernatant and set aside.

[0038] After fully swelling 5 g of CNBr-Sepharose 4B with 1 mmol / L HCl, filter and wash away the additives. Place the column in an equal volume of coupling solution containing 250 μg of anti-HSP70 antibody and shake overnight at 4°C at 40 rpm. Slowly add the gel solution to a prepacked glass column. After complete natural sedimentation, release the outlet and add eluent A (0.1 mol / L NaHCO₃, 0.5 mol / L Tris-HCl, pH 8.0) at a flow rate of approximately 0.8 ml / min. Wash the column three times alternately with eluent B (0.1 mol / L sodium acetate, 0.5 mol / L NaOH, pH 4.0) and eluent C (0.1 mol / L Tris-HCl, 0.5 mol / L NaCl, pH 8.0) at a flow rate of 1 ml / min. Equilibrate with equilibration buffer and incubate overnight at 4°C to obtain a crude protein extract. Slowly add protein crude extract (repeat loading 3 times) at 1 / 10 of the column volume, 0.01mol / LpH7.4 PBS eluent, flow rate 1m / min, wash away unbound proteins, collect PBS eluent, monitor the absorbance of eluent at 260nm wavelength with UV detector, collect eluent with A260nm>0.02, and immediately neutralize with 1mol / LNaHCO3. The eluents were concentrated, desalted with Sep-Pak 18 column, and freeze-dried. The purified heat shock protein 70 peptide was subjected to SDS-PAGE gel electrophoresis, silver staining, and Western blot identification. The results are as follows Figure 1 shown.

[0039] from Figure 1 As can be seen, lane A is the protein eluted with PBS eluent, which does not contain the target protein. Lane B is the protein eluted with desorption solution, which shows that a high concentration of heat shock protein 70 peptide was purified.

[0040] Example 2 Preparation of DR5 Monoclonal Antibody

[0041] DR5 recombinant protein, catalog number: PA2000-348, was purchased from Hubei Aipidi Bioengineering Co., Ltd.

[0042] BALB / c mice were immunized with DR5 recombinant protein. Initially, the protein was mixed with an equal volume of Freund's complete adjuvant and stirred in a homogenizer at 4°C until the protein formed an emulsion. The mouse was then intraperitoneally injected at a dose of 80 μg / mouse. Booster immunizations were performed every 7 days with the same antigen dose emulsified with an equal volume of Freund's incomplete adjuvant for a total of four times. Three days after the final immunization, cell fusion was performed according to conventional methods in the field. Hybridoma cells were screened using an indirect enzyme-linked immunosorbent assay (ELISA). The concentration of DR5 recombinant protein was adjusted to 5 μg / mL, and 100 μL / well of the ELISA plate was coated. After washing with phosphate-tween buffer, the plate was blocked with 5% bovine serum albumin for 1 hour at 37°C. 50 μL of hybridoma cell culture supernatant was added to each well and incubated at 37°C for 1 hour. Myeloma cell culture supernatant was also used as a negative control. After washing with phosphate-tween buffer, 100 μL of alkaline phosphatase-conjugated goat anti-mouse IgG (1:5000) was added and incubated at 37°C for 1 hour. After washing three times with phosphate-Tween buffer, 100 μL of disodium p-nitrophenylphosphate chromogen was added for color development. The reaction was allowed to proceed in the dark for 10 min. D (405 nm) was measured using a microplate reader. Hybridoma supernatants with a P / N ratio ≥ 2.1 were considered positive. The results are shown in Table 1.

[0043] Table 1 Indirect ELISA screening results

[0044] Hybridoma cells Absorbance at 405 nm P / N 2D3 0.453 6.21 3G7 0.567 7.77 5F2 0.492 6.74 Negative control 0.073

[0045] As shown in Table 1, the three hybridoma cell lines exhibited the best positive reactions. After cloning by limiting dilution, a single hybridoma cell line, 3G7, was obtained that stably secreted a monoclonal antibody against the DR5 recombinant protein. This hybridoma cell line was selected for subsequent experiments.

[0046] Ascites was prepared by in vivo ascites induction. 10 BALB / c mice aged 10-12 weeks were sensitized by intraperitoneal injection of paraffin 7 days in advance. 3G7 hybridoma cells were cultured at a density of 1×10 6 Inject 100 cells / mouse, observe the abdomen of the mouse 7-10 days later, and extract ascites when the abdomen is obviously full. Purify the ascites using Protein A / G kit, and the antibody purity is good after SDS-PAGE detection.

[0047] The affinity of the monoclonal antibodies was determined by indirect ELISA. The cells were coated with 0.5 and 0.25 μg / mL DR5 recombinant protein at 100 μL / well at 4°C overnight. 5% skim milk blocking buffer was added at 200 μL / well and incubated at 37°C for 2 h. The obtained 3G7 monoclonal antibody was diluted to 10, 5, 2.5, 1.25, 0.625, 0.313, 0.156, and 0.078 μg / mL at 100 μL / well and incubated at 37°C for 1 h. HRP-labeled goat anti-mouse IgG was added at a 1:10,000 dilution and incubated at 37°C for 45 min. TMB substrate colorimetric solution was added at 100 μL / well and allowed to react at room temperature in the dark for 15 min. The reaction was terminated and the D450 nm value was measured. Plot the antibody-antigen binding curve. Using a graphical method, calculate the affinity constant (Ka) by substituting the antibody concentration (Ab) corresponding to half the maximum D450nm value (i.e., 50% D450nm) for the antigen concentration (Ag) into the formula. Kaff = (n-1) / 2(nAb'-Ab), where Ab and Ab' represent the antibody concentrations (mol / L) that produce half the absorbance when the antigen concentrations are Ag (1 μg / mL) and Ag' (0.5 μg / mL), respectively, and n = Ag / Ag'. Pairwise comparisons were performed to determine the average Kaff value, which was used as the affinity constant for the monoclonal antibody. The dissociation constant (Kd) of the monoclonal antibody is the reciprocal of the affinity constant. The results are shown in Table 2.

[0048] Table 2 Dissociation constants of 3G7 monoclonal antibody

[0049] Antibody Dissociation constant 3G7 monoclonal antibody 8.53nM

[0050] The results showed that 3G7 monoclonal antibody had good affinity.

[0051] The 3G7 hybridoma cells were entrusted to Wuhan Dian Biotechnology Co., Ltd. for variable region sequencing. The results showed that the light chain variable region sequence was as shown in SEQ ID NO: 1, and the heavy chain variable region sequence was as shown in SEQ ID NO: 2.

[0052] Example 3 Detection of Antitumor Activity of 3G7 Monoclonal Antibody and Heat Shock Protein 70 Peptide

[0053] Peripheral anticoagulated blood from healthy adults was separated using lymphocyte separation medium. DCs and T lymphocytes were routinely isolated. DCs were induced in RPMI1640 medium supplemented with 10 μg / L IL-4 and 10 μg / L GM-CSF. On the 5th day, two groups were divided and treated with 50 μg / mL of the heat shock protein 70 peptide prepared in Example 1 to induce DC maturation. DC maturation without heat shock protein 70 peptide served as a control. Lymphocytes were induced in RPMI1640 medium supplemented with 10 μg / L IL-2 and 10 μg / L GM-CSF. On the 7th day, mature DCs were added to each group (DC:T = 10:1). Culture was continued for another 7 days, and specific cytotoxic T lymphocytes (CTLs) were harvested. The MTT assay was used to determine the cytotoxicity of CTLs against tumor cells. TE-11 esophageal cancer cells were seeded into 96-well plates as target cells. After 8 hours of culture and adherence, the two groups of CTLs and unstimulated T lymphocytes (blank control) were added as effector cells, respectively, at an effector-target ratio of 40:1. 100 μg / mL of 3G7 monoclonal antibody was used in combination with CTLs or alone. Each group was plated in triplicate, with three replicates. The groups were:

[0054] Group A: CTL experimental group prepared by DC induced by heat shock protein 70 peptide

[0055] Group B: CTL prepared from DCs induced by heat shock protein 70 peptide + 100 μg / mL 3G7 monoclonal antibody experimental group

[0056] Group C: CTL prepared without heat shock protein 70 peptide-induced DCs and 100 μg / mL 3G7 monoclonal antibody experimental group

[0057] Group D: 100 μg / mL 3G7 monoclonal antibody experimental group

[0058] Group E: CTL experimental group without heat shock protein 70 peptide induction of DC preparation

[0059] Group F: T lymphocyte control group without antigen stimulation

[0060] After each group of cells and / or antibodies were co-incubated with tumor cells for 24 hours, 20 μl of MTT was added to each well, and the mixture was incubated at 37°C for 4 hours. The mixture was centrifuged at 1000 r / min for 10 minutes, and the supernatant was discarded. 200 μl of DMSO was added to dissolve the crystals, and the OD value was measured at 570 nm using a microplate reader. The killing rate was calculated according to the following formula: Killing rate (%) = (1-(D570 nm value of the experimental well-D570 nm value of the effector cell) / D570 nm value of the target cell) × 100%. The results are shown in the figure. Figure 2 shown.

[0061] from Figure 2As can be seen, CTLs generated from DCs induced with heat shock protein 70 peptide in group A demonstrated superior tumor cell killing efficacy compared to CTLs generated without heat shock protein 70 peptide in group E (P<0.05). In group D, 3G7 monoclonal antibody alone also achieved a 60.8% tumor killing rate. Combining the monoclonal antibody with CTLs demonstrated a significant synergistic effect, increasing the tumor killing rate to 86.5%.

[0062] Example 4 Animal treatment experiment

[0063] Mice were randomly divided into 4 groups: model group, monoclonal antibody treatment group, heat shock protein 70 peptide combined with monoclonal antibody group, heat shock protein 70 peptide group, and positive control group. TE-11 esophageal cancer cells were plated at 1×10 7 The tumor was inoculated subcutaneously on the right forelimb of mice at a concentration of 1 mg / mL, and the model was established after 2 weeks (tumors that were too large or too small were eliminated). The model group was injected with 100 μL of normal saline in situ; the monoclonal antibody treatment group was injected with 1 mg / kg of 3G7 monoclonal antibody in situ; the heat shock protein 70 peptide combined with monoclonal antibody group: 1 mg / kg of 3G7 monoclonal antibody was injected in situ, followed by 5 mg / kg of heat shock protein 70 peptide described in Example 1 in situ after an interval of 2 hours; the heat shock protein 70 peptide group: 5 mg / kg of heat shock protein 70 peptide described in Example 1 was injected in situ; the positive control group: 1 mg / kg of trastuzumab was injected in situ. Each group was treated with the drug for 3 consecutive weeks, and then the mice were killed by cervical dislocation after another 3 weeks of feeding. The tumor tissue was removed and the tumor weight was weighed on an electronic balance. The tumor inhibition rate was calculated according to the following formula: Tumor inhibition rate = (average tumor weight of the model group - average tumor weight of the drug treatment group) / average tumor weight of the model group × 100%. The results are shown in Figure 2. Figure 3 shown.

[0064] from Figure 3 The results show that 3G7 monoclonal antibody has a better tumor inhibition effect than the positive control group, with a tumor inhibition rate of 58.7%, while the tumor inhibition rate of the heat shock protein 70 peptide combined with 3G7 monoclonal antibody group reached 83.5%, which also shows that the use of heat shock protein 70 peptide combined with monoclonal antibody treatment has a better therapeutic effect.

[0065] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "examples", "specific examples", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in an appropriate manner in any one or more embodiments or examples. Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and purpose of the present invention, and the scope of the present invention is defined by the claims and their equivalents.

Claims

1. Use of a monoclonal antibody 3G7 specifically targeting DR5 in combination with a heat shock protein peptide in the preparation of a pharmaceutical composition for treating esophageal cancer, wherein the heat shock protein peptide is a heat shock protein 70 peptide, which is obtained by lysing esophageal cancer cells, centrifuging the supernatant, and purifying it with an HSP70 antibody column; the dosage ratio of the monoclonal antibody 3G7 targeting DR5 to the heat shock protein 70 peptide is 1:5, the amino acid sequence of the light chain variable region of the monoclonal antibody 3G7 is shown in SEQ ID NO: 1, and the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:

2.

2. The use according to claim 1, It is characterized in that The pharmaceutical composition further comprises a pharmaceutically acceptable carrier and an excipient.

3. A monoclonal antibody 3G7 that specifically targets DR5, Features The amino acid sequence of the light chain variable region is shown in SEQ ID NO: 1, and the amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO: 2.

Citation Information

Patent Citations

  • Method for regulating expression, quantity and activity of heat shock protein 70 and application thereof

    CN102816792A

  • Compound of esophagus cancer-related peptides and heat shock proteins and use thereof

    CN104211773A

  • ScFv antibody of human heat shock protein gp96 as well as preparing method and application thereof

    CN104356233A

  • Medicine composition containing genetically modified oncolytic virus, and application of medicine composition in cancer treatment

    CN113425856A

  • Anti-human trail receptor dr5 monoclonal antibody (ad5-10), method thereof and use of the same

    US20100080806A1